Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker
Mike J. Mason(Sage Bionetworks), Justin Guinney(Sage Bionetworks), Dirk Hose(Gavi), Douglas Bassett, Fred K. Gruber(GNS Healthcare (United States)), Fadi Towfic, Andrew Dervan, Yi Cui(Kunming University of Science and Technology), Anjan Thakurta(University of Oxford), Brian S. White(University of Utah), Mehmet Samur(Dana-Farber Cancer Institute), Brian A. Walker(University of Miami), Carolina Schinke(University of Arkansas for Medical Sciences), Boris Hayete(GNS Healthcare (United States)), Kenneth H. Shain(Moffitt Cancer Center), Daniel Auclair(Multiple Myeloma Research Foundation), Hartmut Goldschmidt(Heidelberg University), Hervé Avet‐Loiseau(Institut universitaire du cancer de Toulouse Oncopole), Thomas Yu(Sage Bionetworks), Christine Eng(Genome Institute of Singapore), Jonathan Göke(Genome Institute of Singapore), Matthew Trotter, Gareth J. Morgan(Hywel Dda University Health Board), Bailiang Li(Stanford University), Hongyue Dai(Rosetta Stone (United States)), Nikhil Munshi(Johns Hopkins University), María Ortiz, Erin Flynt, William S. Dalton(Moffitt Cancer Center), Pieter Sonneveld(Erasmus MC Cancer Institute)
Cited by 0
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.2k